Healthcare company Organon (NYSE:OGN) announced on Friday that it has entered into an agreement to divest its JADA System to Laborie Medical Technologies Corp, a diagnostic and therapeutic medical technology company, for up to USD465m.

The deal includes USD440m at closing and a potential USD25m contingent on 2026 revenue targets. The total value represents 6.5 times JADA's trailing 12-month revenue, reflecting its successful launch and US expansion.

Around 100 employees are expected to transfer to Laborie as part of the transaction.

Organon acquired JADA in June 2021. The device treats abnormal postpartum uterine bleeding using a low-level intrauterine vacuum.

Net proceeds will be applied to debt reduction, supporting Organon's deleveraging strategy and future investment in women's health biopharma and other strategic priorities.

The transaction has board approval and is expected to close in the first quarter of 2026, subject to regulatory clearance and other customary closing conditions.